Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
This is a prospective open-label one-arm phase III trial designed to evaluate the safety and efficacy of letrozole 2.5 mg administered orally daily for 24 months as adjuvant therapy in postmenopausal patients with primary breast cancer.

This trial is not recruiting patients in the United States.
Breast Cancer
DRUG: Letrozole
Rate of patients without recurrence after 24 months of Letrozole treatment as assessed by radiological imaging, after 24 months
Disease free survival (DFS), every 6 months for 24 months|Quality of life as assessed by EORTC QLQ-C30 + BR23 every 3 months, Every 6 months|Safety and tolerability with assessments incuding biochemistry, hematology, ECG, pyhsical exam and AE documentation, every 6 months
This is a prospective open-label one-arm phase III trial designed to evaluate the safety and efficacy of letrozole 2.5 mg administered orally daily for 24 months as adjuvant therapy in postmenopausal patients with primary breast cancer.

This trial is not recruiting patients in the United States.